Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in LeMaitre Vascular, Inc., Butterfly Network or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how LeMaitre Vascular, Inc., Butterfly Network and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About LeMaitre Vascular, Inc., Butterfly Network and Inc.

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. The company offers Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging on a single handheld probe integrated with the clinical workflow, and accessible on a user’s smartphone, tablet, and almost any hospital computer system; Butterfly Move, merging the mobility of a handheld with the stability of a full cart system; and iQ+ Bladder, a specialty product for bladder scanning market. It also provides Compass AI which offers one system to connect every device, workflow, and department; ScanLab, an AI-powered educational platform that provides written walkthroughs and reference imagery to guide real-time educational scanning; and Butterfly iQ+/iQ3 Vet, a third generation handheld ultrasound system. It sells and markets its products through a direct sales force, distributors, and e-commerce channels. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.

Latest Health Care Equipment & Supplies and LeMaitre Vascular, Inc., Butterfly Network, Inc. Stock News

As of June 18, 2026, LeMaitre Vascular, Inc. had a $2.1 billion market capitalization, compared to the Health Care Equipment & Supplies median of $350.0 million. LeMaitre Vascular, Inc.’s stock is up 15.8% in 2026, up 2.2% in the previous five trading days and up 15.97% in the past year.

Currently, LeMaitre Vascular, Inc.’s price-earnings ratio is 34.5. LeMaitre Vascular, Inc.’s trailing 12-month revenue is $256.3 million with a 24.3% net profit margin. Year-over-year quarterly sales growth most recently was 11.2%. Analysts expect adjusted earnings to reach $3.000 per share for the current fiscal year. LeMaitre Vascular, Inc. currently has a 1.1% dividend yield.

As of June 18, 2026, Butterfly Network, Inc. had a $2.3 billion market cap, putting it in the 56th percentile of all stocks. Butterfly Network, Inc.’s stock is up 134.2% in 2026, up 60.6% in the previous five trading days and up 304.55% in the past year.

Currently, Butterfly Network, Inc. does not have a price-earnings ratio. Butterfly Network, Inc.’s trailing 12-month revenue is $102.9 million with a -73.6% net profit margin. Year-over-year quarterly sales growth most recently was 25.0%. Analysts expect adjusted earnings to reach $-0.128 per share for the current fiscal year. Butterfly Network, Inc. does not currently pay a dividend.

How We Compare LeMaitre Vascular, Inc., Butterfly Network and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at LeMaitre Vascular, Inc., Butterfly Network and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

LeMaitre Vascular, Inc., Butterfly Network and Inc. Stock Value Grades

Company	Ticker	Value
LeMaitre Vascular, Inc.	LMAT	F
Butterfly Network, Inc.	BFLY	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

LeMaitre Vascular, Inc. has a Value Score of 15, which is Ultra Expensive. Butterfly Network, Inc. has a Value Score of 4, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither LeMaitre Vascular, Inc., Butterfly Network or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if LeMaitre Vascular, Inc., Butterfly Network or Inc. is the better investment when it comes to value.

LeMaitre Vascular, Inc., Butterfly Network and Inc.’s Quality Grades

Company	Ticker	Quality
LeMaitre Vascular, Inc.	LMAT	A
Butterfly Network, Inc.	BFLY	D

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

LeMaitre Vascular, Inc. has a Quality Score of 81, which is Very Strong. Butterfly Network, Inc. has a Quality Score of 33, which is Weak.

The Quality Grade Winner: LeMaitre Vascular, Inc.

As you can clearly see from the Quality Grade breakdown above, LeMaitre Vascular, Inc. has a better overall quality grade than Butterfly Network, Inc.. For investors who are looking for companies with higher quality than others in the same industry, LeMaitre Vascular, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

LeMaitre Vascular, Inc., Butterfly Network and Inc.’s Momentum Grades

Company	Ticker	Momentum
LeMaitre Vascular, Inc.	LMAT	C
Butterfly Network, Inc.	BFLY	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

LeMaitre Vascular, Inc. has a Momentum Score of 43, which is Average. Butterfly Network, Inc. has a Momentum Score of 97, which is Very Strong.

The Momentum Grade Winner: Butterfly Network, Inc.

As you can clearly see from the Momentum Grade breakdown above, Butterfly Network, Inc. is considered to have stronger momentum compared to LeMaitre Vascular, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Butterfly Network, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other LeMaitre Vascular, Inc., Butterfly Network and Inc. Grades

In addition to Momentum, Quality and Value, A+ Investor also provides grades for Growth and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether LeMaitre Vascular, Inc., Butterfly Network and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, LeMaitre Vascular, Inc., Butterfly Network or Inc. Stock?

Overall, LeMaitre Vascular, Inc. stock has a Value Score of 15, Momentum Score of 43 and Quality Score of 81.

Butterfly Network, Inc. stock has a Value Score of 4, Momentum Score of 97 and Quality Score of 33.

Comparing LeMaitre Vascular, Inc., Butterfly Network and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.